Spravato, a nasal spray used for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior, generated approximately $1.05 billion in worldwide sales in 2023 [1]. This figure represents a significant increase from the previous year, with sales in 2022 reaching around $783 million [1].
How is Spravato's Revenue Growing?
The growth in Spravato's revenue is attributed to its expanding market presence and indications [1]. In 2023, its sales in the United States reached approximately $750 million, while international sales contributed around $300 million [1]. This demonstrates a consistent upward trend in its commercial performance.
When Does Spravato's Patent Protection End?
Spravato, the brand name for esketamine nasal spray, is protected by patents. Information regarding the specific expiration dates of these patents and potential market entry for generics can be found on DrugPatentWatch.com [2]. Understanding patent exclusivity is crucial for anticipating the competitive landscape and the timeline for potential generic alternatives.
What are the Approved Uses for Spravato?
Spravato has received regulatory approval for two primary indications. It is used in conjunction with an oral antidepressant in adult patients diagnosed with treatment-resistant depression. Additionally, it is indicated for depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior [3].
Are There Any Alternatives to Spravato?
For patients with treatment-resistant depression, various treatment options exist. These can include other pharmacologic approaches, such as augmentation strategies with different antidepressant classes, or non-pharmacologic interventions like electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) [4]. The choice of treatment is highly individualized and depends on patient characteristics, treatment history, and response [4].